CICC Maintains "Outperform" Rating on Sino Biopharm (01177) with HK$8.9 Target Price

Stock News01-15

CICC has released a research report reiterating its HK$8.9 target price and "Outperform" rating for Sino Biopharm (01177). The firm has kept its adjusted net profit forecasts for 2025 and 2026 unchanged at 4.47 billion yuan and 4.921 billion yuan, respectively, while introducing a new forecast of 5.423 billion yuan for 2027. The report notes the company's announcement of a 100% acquisition of Hejiya Biotech for a consideration of 1.2 billion yuan. Hejiya Biotech has a deep focus on the siRNA field, with key strategic layouts in three major chronic disease areas: weight-loss and metabolism, cardiovascular and cerebrovascular diseases, and the nervous system; its core platform possesses a differentiated competitive advantage. The report suggests that existing therapies in the chronic disease sector often face limitations in efficacy, safety risks, and low patient adherence, indicating a vast unmet clinical need. This acquisition is expected to assist Sino Biopharm in building a next-generation innovative pipeline for cardiovascular treatment and enhancing its strategic position in the weight-loss and metabolism field. Furthermore, the company's well-established R&D system and sales channels are anticipated to rapidly advance Hejiya Biotech's clinical progress and subsequent commercialization, creating potential for synergistic benefits for both parties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195281347?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 16:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195281347","market":"hk","top_or_hot":-1,"title":"CICC Maintains \"Outperform\" Rating on Sino Biopharm (01177) with HK$8.9 Target Price","media":"Stock News","content":"<p>CICC has released a research report reiterating its HK$8.9 target price and \"Outperform\" rating for Sino Biopharm (01177). The firm has kept its adjusted net profit forecasts for 2025 and 2026 unchanged at 4.47 billion yuan and 4.921 billion yuan, respectively, while introducing a new forecast of 5.423 billion yuan for 2027. The report notes the company's announcement of a 100% acquisition of Hejiya Biotech for a consideration of 1.2 billion yuan. Hejiya Biotech has a deep focus on the siRNA field, with key strategic layouts in three major chronic disease areas: weight-loss and metabolism, cardiovascular and cerebrovascular diseases, and the nervous system; its core platform possesses a differentiated competitive advantage. The report suggests that existing therapies in the chronic disease sector often face limitations in efficacy, safety risks, and low patient adherence, indicating a vast unmet clinical need. This acquisition is expected to assist Sino Biopharm in building a next-generation innovative pipeline for cardiovascular treatment and enhancing its strategic position in the weight-loss and metabolism field. Furthermore, the company's well-established R&D system and sales channels are anticipated to rapidly advance Hejiya Biotech's clinical progress and subsequent commercialization, creating potential for synergistic benefits for both parties.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CICC Maintains \"Outperform\" Rating on Sino Biopharm (01177) with HK$8.9 Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCICC Maintains \"Outperform\" Rating on Sino Biopharm (01177) with HK$8.9 Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-15 16:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CICC has released a research report reiterating its HK$8.9 target price and \"Outperform\" rating for Sino Biopharm (01177). The firm has kept its adjusted net profit forecasts for 2025 and 2026 unchanged at 4.47 billion yuan and 4.921 billion yuan, respectively, while introducing a new forecast of 5.423 billion yuan for 2027. The report notes the company's announcement of a 100% acquisition of Hejiya Biotech for a consideration of 1.2 billion yuan. Hejiya Biotech has a deep focus on the siRNA field, with key strategic layouts in three major chronic disease areas: weight-loss and metabolism, cardiovascular and cerebrovascular diseases, and the nervous system; its core platform possesses a differentiated competitive advantage. The report suggests that existing therapies in the chronic disease sector often face limitations in efficacy, safety risks, and low patient adherence, indicating a vast unmet clinical need. This acquisition is expected to assist Sino Biopharm in building a next-generation innovative pipeline for cardiovascular treatment and enhancing its strategic position in the weight-loss and metabolism field. Furthermore, the company's well-established R&D system and sales channels are anticipated to rapidly advance Hejiya Biotech's clinical progress and subsequent commercialization, creating potential for synergistic benefits for both parties.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000165453.HKD","symbol_name":"华夏精选大中华科技基金 A类港币","start_time":0,"source_url":"","article_id":"1195281347","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195281347","pubTimestamp":1768466192,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CICC has released a research report reiterating its HK$8.9 target price and \"Outperform\" rating for Sino Biopharm (01177). The firm has kept its adjusted net profit forecasts for 2025 and 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1589":"北水核心资产","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","01177":"中国生物制药"},"translate_title":"中金维持中国生物医药(01177)“跑赢大市”评级目标价8.9港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"CICC has released a research report reiterating its HK$8.9 target price and \"Outperform\" rating for Sino Biopharm (01177). The firm has kept its adjusted net profit forecasts for 2025 and 2026 unchanged at 4.47 billion yuan and 4.921 billion yuan, respectively, while introducing a new forecast of 5.423 billion yuan for 2027. The report notes the company's announcement of a 100% acquisition of Hejiya Biotech for a consideration of 1.2 billion yuan. Hejiya Biotech has a deep focus on the siRNA field, with key strategic layouts in three major chronic disease areas: weight-loss and metabolism, cardiovascular and cerebrovascular diseases, and the nervous system; its core platform possesses a differentiated competitive advantage. The report suggests that existing therapies in the chronic disease sector often face limitations in efficacy, safety risks, and low patient adherence, indicating a vast unmet clinical need. This acquisition is expected to assist Sino Biopharm in building a next-generation innovative pipeline for cardiovascular treatment and enhancing its strategic position in the weight-loss and metabolism field. Furthermore, the company's well-established R&D system and sales channels are anticipated to rapidly advance Hejiya Biotech's clinical progress and subsequent commercialization, creating potential for synergistic benefits for both parties.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195281347","isCrawlerRequest":true}